Sanjivani Paranteral Ltd
SANJIVINSanjivani Paranteral Ltd
SANJIVINPrice Chart
Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
64.24 | 15.89 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.49 | 6.67 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Sanjivani Paranteral is engaged in the business of pharmaceutical products.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 116.21 | 35.52 | 18.45 | 26.05 | 16.61 | 25.36 | 30.85 | 42.02 | 59.47 | 63.18 | ||||||||||
Raw Materials | 110.80 | 28.67 | 24.94 | 14.60 | 9.93 | 14.14 | 12.66 | 19.84 | 34.37 | 53.09 | ||||||||||
Power & Fuel Cost | 1.05 | 0.96 | 1.08 | 0.73 | 0.58 | 0.78 | 0.98 | 1.10 | 1.14 | |||||||||||
Employee Cost | 2.60 | 2.77 | 2.96 | 2.37 | 2.25 | 2.13 | 2.73 | 2.91 | 3.74 | |||||||||||
Selling & Administrative Expenses | 4.08 | 5.09 | 3.11 | 2.76 | 2.60 | 2.91 | 7.22 | 5.32 | 9.45 | |||||||||||
Operating & Other expenses | 2.48 | 18.45 | 38.09 | 6.39 | 1.33 | 3.01 | 1.30 | 6.66 | 2.01 | |||||||||||
EBITDA | -4.80 | -20.42 | -51.73 | -0.80 | -0.08 | 2.39 | 5.96 | 6.19 | 8.76 | 10.09 | ||||||||||
Depreciation/Amortization | 1.36 | 1.20 | 1.19 | 1.17 | 1.07 | 0.86 | 0.88 | 0.89 | 0.93 | 0.76 | ||||||||||
PBIT | -6.16 | -21.62 | -52.92 | -1.97 | -1.15 | 1.53 | 5.08 | 5.30 | 7.83 | 9.33 | ||||||||||
Interest & Other Items | 8.81 | 4.79 | 0.45 | 0.33 | 0.66 | 0.13 | 0.21 | 0.36 | 0.25 | 0.37 | ||||||||||
PBT | -14.97 | -26.41 | -53.37 | -2.30 | -1.81 | 1.40 | 4.87 | 4.94 | 7.58 | 8.96 | ||||||||||
Taxes & Other Items | -0.33 | -0.19 | -0.32 | -0.23 | -0.10 | -0.01 | 0.03 | 0.43 | 1.41 | 2.06 | ||||||||||
Net Income | -14.64 | -26.22 | -53.05 | -2.07 | -1.71 | 1.41 | 4.84 | 4.51 | 6.17 | 6.90 | ||||||||||
EPS | -24.82 | -44.45 | -89.94 | -3.51 | -2.90 | 1.96 | 5.23 | 4.51 | 5.69 | 5.91 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Sanjivani Paranteral Ltd | 71.84 | 15.89 | — |
Sun Pharmaceutical Industries Ltd | 46.13 | 6.58 | 0.73% |
Cipla Ltd | 29.21 | 4.49 | 0.87% |
Mankind Pharma Ltd | 62.91 | 12.57 | — |
Price Comparison
Compare SANJIVIN with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 1.16%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Feb 2024
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
SANJIVIN has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Net profit of Sanjivani Paranteral rose 34.50% to Rs 2.30 crore in the quarter ended September 2024 as against Rs 1.71 crore during the previous quarter ended September 2023. Sales rose 29.50% to Rs 18.13 crore in the quarter ended September 2024 as against Rs 14.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales18.1314.00 30 OPM %15.7715.14 - PBDT3.072.22 38 PBT2.921.99 47 NP2.301.71 35 Powered by Capital Market - Live
Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live
Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 9 September 2024.Powered by Capital Market - Live
Sanjivani Paranteral announced that the 30th Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live
Sanjivani Paranteral standalone net profit rises 10.32% in the June 2024 quarter
Net profit of Sanjivani Paranteral rose 10.32% to Rs 1.71 crore in the quarter ended June 2024 as against Rs 1.55 crore during the previous quarter ended June 2023. Sales rose 30.68% to Rs 16.44 crore in the quarter ended June 2024 as against Rs 12.58 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales16.4412.58 31 OPM %14.1715.98 - PBDT2.402.03 18 PBT2.271.80 26 NP1.711.55 10 Powered by Capital Market - Live
Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 6 August 2024.Powered by Capital Market - Live
Sanjivani Paranteral standalone net profit rises 1.44% in the March 2022 quarter
Sanjivani Paranteral standalone net profit rises 344.00% in the September 2021 quarter
Sanjivani Paranteral reports standalone net profit of Rs 0.63 crore in the June 2021 quarter
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 17.95%, vs industry avg of 9.04%
Increasing Market Share
Over the last 5 years, market share increased from 0.01% to 0.02%